HALO News and Press, Halozyme Therapeutics Inc. From 04/13/22

Shares of the drug delivery specialist Antares Pharma (NASDAQ: ATRS) jumped by as much as 49.2% in premarket action Wednesday morning. The company's stock is bolting higher in response to a $960 million definitive merger agreement with Halozyme (NASDAQ: HALO) . Per the t...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday! Source: f11photo/Shutterstock.com Moving stocks this morning are earnings reports, acquisition deals, insider buy...

Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader PR Newswire Transaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Financial Growth Through 2027 and Bey...

Halozyme Therapeutics (NASDAQ:HALO) is nearing a deal to acquire Antares Pharma (NASDAQ:ATRS) for ~960M, The Wall Street Journal reported citing people familiar with the matter. The deal could be announced today, April 13. Shares of Antares rose +44.39% to $5.40 pre-market Apri...

Genmab (GMAB) said an arbitral tribunal has ruled in favor of Johnson & Johnson's (NYSE:JNJ) Janssen Biotech in both matters related to royalty payments under their license agreement related to cancer drug daratumumab. On the first issue, the tribunal determined by maj...

Halozyme Therapeutics (NASDAQ:HALO) has granted Chugai a license to its ENHANZE drug delivery technology for use in an undisclosed target. The ENHANZE technology is based on the recombinant human hyaluronidase PH20 enzyme (rHuPH20). Terms of the collaboration and license agreement call f...

Halozyme Therapeutics, Inc. and Chugai Pharmaceutical Enter Global Collaboration and License Agreement for ENHANZE® Technology PR Newswire SAN DIEGO , March 24, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a global ...

Positive Topline Results Announced from ADAPT-SC Study Evaluating Subcutaneous Efgartigimod Using ENHANZE® Drug Delivery Technology for Generalized Myasthenia Gravis PR Newswire - Study met primary endpoint, demonstrating noninferior total IgG reduction at day 29 ...

Halozyme Appoints Moni Miyashita to Board of Directors PR Newswire SAN DIEGO , March 15, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of Moni Miyashita to its board of directors. Ms. Miyashita is an a...

I was drawn to Halozyme due to its business model that is devoid of in-house drug development. Halozyme reformulates many blockbuster drugs that provided them with significant milestones and royalty. What is more, the impressive number of partners diversifies their revenue sources and...